Pulmonx develops and provides a clinically proven bronchoscopic treatment for patients with severe COPD and emphysema using Zephyr® Valves.

Pulmonx

Pulmonx Corporation | 17,077 followers on LinkedIn. Improving Breathing and Quality of Life for Emphysema and Advanced COPD Patients | Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced.

Kelly Shriner

Russel Haskin

Medical Technology Sales & Marketing Executive | Market Development | Strategies | EMEA incl Emerging Markets | Digital Transformation | GoTo…

Gaelle Flammang- Dorie

Marilyn Cornelious

Pulmonx Corporation

Zephyr Valves will be featured at Pulmonology On Air 2024, a virtual event designed for peer-to-peer learning among pulmonologists. Don’t miss this opportunity to witness live endobronchial valve procedures and learn how Zephyr Valves can benefit your patients with severe COPD/emphysema. Pulmonx is proud to sponsor this event. Register here: https://bit.ly/4ez40kc #Pulmonology #EndobronchialValves #BLVR #InterventionalPulmonology #ZephyrValves #Pulmonx #COPD #Emphysema #PulmonologyOnAir

Pulmonx employees walked together in support of COPD Awareness and the importance of knowing your lung function. While November shines a light on COPD, lung health is a conversation we need to have all year long. Early detection can lead to better treatment options, including Zephyr Valves for severe COPD/emphysema. Let's keep raising awareness and advocating for lung health! https://bit.ly/3O69Xub #COPDawareness #KnowYourLungFunction #BetterBreathingTogether

We’re live at the GOLD International COPD Conference in Philadelphia! Stop by Booth #25 to meet the Pulmonx team and learn how our Zephyr Endobronchial Valves are making a difference for severe #COPD / #emphysema patients. Join us in our mission of "Fighting every day, for every breath, so our patients don't have to." Let’s connect and explore how we can improve patient care together. Looking forward to seeing you here! #PulmonaryHealth #ZephyrValves #GOLD2024 #BLVR #Pulmonx

Today, we would like to pay tribute to the veterans who have served our nation with unwavering courage. John, an Air Force veteran with severe COPD/emphysema has seen a 20-25% improvement in lung function after being treated with Zephyr Valves. Read John’s story and join us in celebrating the resilience of our country’s veterans: https://bit.ly/3YiQKdJ Results may vary. #ZephyrValves #BreatheBetter #VeteransDay

#EndobronchialValves have been included in the GOLD Report since 2017 as part of the standard of care for treating severe COPD/emphysema. Download the GOLD Report Summary here. https://bit.ly/4fuV2p8 We’re excited to be a part of the 9th Annual GOLD International COPD Conference on November 11-12 in Philadelphia! Visit Pulmonx at Booth #25 to explore how Zephyr Endobronchial Valves can help severe COPD/emphysema patients breathe easier. Let’s connect and discuss the latest innovations in COPD care. See you there! #COPD #Emphysema #PulmonaryHealth #ZephyrValves #Pulmonx #GOLD2024 #BLVR #ChronicDiseaseCare

We recently hosted an engaging International Zephyr Valve Users Group Meeting in Bali during the WCBIP Meeting. With attendees from across the globe — Australia, New Zealand, Japan, Hong Kong, Germany, Spain, France, Netherlands, and the U.S. — the event was filled with valuable insights about successful endobronchial valve treatment for severe emphysema. Special thanks to Prof. ali musani for moderating, Prof. Dirk-Jan Slebos for the keynote, and Prof. Kaid Darwiche for leading case discussions. A big thank you to the treating physicians who shared their clinical experiences! #ZephyrValves #Pulmonx #BLVR #Emphysema #COPD #ForEveryBreath

Excited for our partnership with the Association of Pulmonary Advanced Practice Providers to bring advanced treatments like Zephyr Valves to more severe COPD/emphysema patients.

Today is National Lung Health Day – a great time to talk with your severe COPD/emphysema patients who are experiencing breathlessness and looking for a treatment to help manage their symptoms. Check out these educational resources for Zephyr Valves: https://bit.ly/4hgGRFM #BLVR #ZephyrValves #Pulmonology

Today, we celebrate the Respiratory Therapists who support COPD patients to help manage their symptoms. We’d like to give a special shoutout to those RTs who support Zephyr Valve patients in their severe COPD/emphysema journey. #RespiratoryTherapists #RCWeek24 #BLVR #LungValves

Pulmonx is excited to be part of the World Congress for Bronchology and Interventional Pulmonology (WCBIP) this year in Bali, Indonesia! Join us at Booth #8 to discover how our Zephyr Endobronchial Valves are transforming care for severe COPD/emphysema patients. This is a fantastic opportunity to connect with global experts, learn about the latest advancements in respiratory medicine, and explore innovative solutions in #InterventionalPulmonology . In the meantime, explore valuable tools and information on improving patient care with Zephyr Valves. https://bit.ly/3BNFiyX We look forward to seeing you in Bali as we continue "Fighting every day for every breath, so our patients don't have to." #WCBIP2024 #Pulmonx #ZephyrValves #BLVR #COPD #Emphysema #RespiratoryHealth

HSTS

DNSSEC

Amazon

Cloudflare CDN

Cloudflare Hosting

Person Schema

Cloudflare

Google Apps for Business

Gravatar Profiles

Cloudflare Network Error Logging

Chief Commercial Officer

Beran Rose

General Counsel

David Lehman

Chief Financial Officer

Derrick Sung

Assistant General Counsel

Lauren Lewis

Chief People Officer

Lisa Paul

Executive Partner, Co-Founder

Ross Longhini

SVP & General Manager, Europe Middle-East & Africa

Jerome Erath

VP, Corporate Controller

John McKune

Vice President, Patient Access

VP, Finance and Administration

Lauren Cristina

Staffan Lindstrand

Michael J. Ryan

Vice President, Corporate Strategy & Business Development

Interim Chief Financial Officer

Mehul Joshi

Mahtab Fatemi

VP RA/QA

Glen French

Jim Bobbitt

Regional Business Director

Marcee M. Maroney

Vice President

David M. Renzi

Senior Vice President

Companies With More Than $1M in Revenue (Top 10K)

United States Public Companies With More Than $50M in Revenue

California Companies that Exited (Top 10K)

Silicon Valley Public Companies

Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.

CIBC Innovation Banking

Debt Financing - Pulmonx

Ally Bridge Group

Series H - Pulmonx

Series G - Pulmonx

Boston Scientific

Series F - Pulmonx

Private Equity Round - Pulmonx

HealthCap

Kleiner Perkins

Series C - Pulmonx

Venture Round - Pulmonx

DeNovo Ventures

Series B - Pulmonx

Redwood City

California

United States

North America

Pulmonx to Present at the Stifel 2024 Healthcare Conference

Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference

Pulmonx: Low Bar For Q2 Earnings (NASDAQ:LUNG)

Cloudflare director Carl Ledbetter sells shares worth over $640k By Investing.com

Pulmonx exec sells over $10,000 in company stock By Investing.com

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation (LUNG) Q1 2024 Earnings Call Transcript

Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript

Earnings call: Pulmonx sees 30% sales boost in Q1, eyes $84M annual target

A minimally invasive device for treating severe emphysema, reducing hyperinflation and improving lung function without the need for surgery.

A diagnostic system used during bronchoscopy to measure airflow and resistance, helping in the assessment of lung compartments for treatment with Zephyr Valves.

Australia

Oceania

United Kingdom

Europe

Canada

New Zealand

HTML5

GlobalSign

DigiCert

Bootstrap

Gravity Forms

Wordpress

Office 365

Google Tag Manager

Vimeo

Google Analytics

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

news impact assignment basic	general
public peers	general	Nov 18, 2024 3:11 PM	c46e67df
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 18, 2024 3:11 PM	287a513c
crunchbase trigger	general	Nov 18, 2024 3:11 PM	5cc13186
crunchbase profile	general	Nov 19, 2024 4:48 AM	b703009a
li profile	general	Nov 18, 2024 3:11 PM	8f20115d
translate crunchbase fundingrounds	general	Nov 19, 2024 5:12 AM	3ce4e9d2
peers	general	Nov 18, 2024 3:11 PM	7f4a95fe
news basic	general	Nov 18, 2024 3:11 PM	e309cd3b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:PULMONX

Pulmonx

Last Close

6.42

22/11 21:00

Market Cap

246.48M

Beta: -

Volume Today

256.08K

Avg: -